Continuous dopaminergic stimulation therapy for Parkinson's disease - Recent advances

Current Opinion in Neurology

Volumn 29, Issue 4, 2016, Pages 474-479

  Timpka, Jonathan ^a,b   Mundt Petersen, Ulrika ^a,b   Odin, Per ^a,b,c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Central Hospital   (Germany)

Author keywords

antiparkinson agents; continuous dopaminergic stimulation; continuous drug delivery; drugs; investigational; Parkinson's disease

Indexed keywords

CARBIDOPA PLUS LEVODOPA; ROTIGOTINE; ANTIPARKINSON AGENT; CARBIDOPA; CARBIDOPA, LEVODOPA DRUG COMBINATION; DELAYED RELEASE FORMULATION; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG COMBINATION; GEL; LEVODOPA; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

CLINICAL FEATURE; CONTINUOUS DOPAMINERGIC STIMULATION THERAPY; DEVELOPMENT; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DYSKINESIA; FOLLOW UP; HUMAN; INFUSION THERAPY; OPEN STUDY; PARKINSON DISEASE; QUALITY OF LIFE; REVIEW; UNIFIED PARKINSON DISEASE RATING SCALE; CUTANEOUS DRUG ADMINISTRATION; DELAYED RELEASE FORMULATION; DRUG COMBINATION; GEL;

ADMINISTRATION, CUTANEOUS; ANTIPARKINSON AGENTS; CARBIDOPA; DELAYED-ACTION PREPARATIONS; DOPAMINE AGONISTS; DRUG COMBINATIONS; GELS; HUMANS; LEVODOPA; PARKINSON DISEASE; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 84973299611     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000354     Document Type: Review

References (38)

1. Van Gerpen JA, Kumar N, Bower JH, et al. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 2006; 63:205-209.
2. Bastide MF, Meissner WG, Picconi B, et al. Pathophysiology of L-dopainduced motor and non-motor complications in Parkinson's disease. Prog Neurobiol 2015; 132:96-168.
3. Lee J-Y, Seo S, Lee JS, et al. Putaminal serotonergic innervation: monitoring dyskinesia risk in Parkinson disease. Neurology 2015; 85:853-860.
4. Quinn N, Marsden CD, Parkes JD. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Lancet 1982; 2:412-415.
5. Shoulson I, Glaubiger GA, Chase TN. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975; 25:1144-1148.
6. Nutt JG, Woodward WR, Hammerstad JP, et al. The ''on-off'' phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984; 310:483-488.
7. Quinn N, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 1984; 34:1131-1136.
8. Rosin AJ, Devereux D, Eng N, Calne DB. Parkinsonism with ''on-off'' phenomena. Intravenous treatment with levodopa after major abdominal surgery. Arch Neurol 1979; 36:32-34.
9. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014; 13:141-149.
10. Slevin JT, Fernandez HH, Zadikoff C, et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients. J Parkinsons Dis 2015; 5:165-174.
11. Fernandez HH, Standaert DG, Hauser RA, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord 2015; 30:500-509.
12. Antonini A, Yegin A, Preda C, et al. Global long-term study on motor and nonmotor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. Parkinsonism Relat Disord 2015; 21:231-235.
13. Martinez-Martin P, Reddy P, Katzenschlager R, et al. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease. Mov Disord 2015; 30:510-516.
14. Antonini A, Fung VSC, Boyd JT, et al. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients. Mov Disord 2016; 31:530-537.
15. Timpka J, Fox T, Fox K, et al. Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease. Acta Neurol Scand 2016; 133:451-458.
16. Buongiorno M, Antonelli F, Cámara A, et al. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: the Barcelona registry. Parkinsonism Relat Disord 2015; 21:871-876.
17. Borgemeester RWK, Drent M, van Laar T. Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients. Parkinsonism Relat Disord 2016; 23:17-22.
18. Todorova A, Samuel M, Brown RG, Chaudhuri KR. Infusion therapies and development of impulse control disorders in advanced Parkinson disease: clinical experience after 3 years' follow-up. Clin Neuropharmacol 2015; 38:132-134.
19. Trenkwalder C, Chaudhuri KR, Ruiz PJG, et al. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease-clinical practice recommendations. Parkinsonism Relat Disord 2015; 21:1023-1030.
20. Odin P, Chaudhuri KR, Slevin JT, et al. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: consensus from an international survey and discussion program. Parkinsonism Relat Disord 2015; 21:1133-1144.
21. Giladi N, Caraco Y, Gureritch T, et al. Pharmacokinetics and safety of ND0612L (levodopa/carbidopa for subcutaneous infusion): results from a phase II study in moderate to severe Parkinson's disease (P1. 187). 67th American Academy of Neurology Annual Meeting 2015; April 2015, Washington, DC, USA.
22. Lang AE, Rodriguez RL, Boyd JT, et al. Integrated safety of levodopacarbidopa intestinal gel from prospective clinical trials. Mov Disord 2016; 31:538-546.
23. van Laar T, Nyholm D, Nyman R. Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease. Acta Neurol Scand 2016; 133:208-215.
24. Metman LV, Stover N, Chen C, et al. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease. Mov Disord 2015; 30:1222-1228.
25. Poewe W, Antonini A. Novel formulations and modes of delivery of levodopa. Mov Disord 2015; 30:114-120.
26. Waters CH, Nausieda P, Dzyak L, et al. Long-term treatment with extendedrelease carbidopa-levodopa (IPX066) in early and advanced Parkinson's disease: a 9-month open-label extension trial. CNS Drugs 2015; 29:341-350.
27. Sieb JP, Themann P, Warnecke T, et al. Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study. Curr Med Res Opin 2015; 31: 967-974.
28. Kim J-M, Chung SJ, Kim JW, et al. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study. BMC Neurol 2015; 15:17.
29. Chung SJ, Kim J-M, Kim JW, et al. Switch from oral pramipexole or ropinirole to rotigotine transdermal system in advanced Parkinson's disease: an open-label study. Expert Opin Pharmacother 2015; 16:961-970.
30. Timmermann L, Asgharnejad M, Boroojerdi B, et al. Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity. Expert Opin Pharmacother 2015; 16:1423-1433.
31. Antonini A, Bauer L, Dohin E, et al. Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms-results of a double-blind, randomized, placebo-controlled trial. Eur J Neurol 2015; 22:1400-1407
32. Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011; 26:90-99.
33. Serrao M, Ranavolo A, Conte C, et al. Effect of 24-h continuous rotigotine treatment on stationary and non-stationary locomotion in de novo patients with Parkinson disease in an open-label uncontrolled study. J Neurol 2015; 262:2539-2547.
34. Woitalla D, Kassubek J, Timmermann L, et al. Reduction of gastrointestinal symptoms in Parkinson's disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial. Parkinsonism Relat Disord 2015; 21:199-204.
35. Hirano M, Isono C, Sakamoto H, et al. Rotigotine transdermal patch improves swallowing in dysphagic patients with Parkinson's disease. Dysphagia 2015; 30:452-456.
36. Rascol O, Zesiewicz T, Chaudhuri KR, et al. A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on Parkinson's disease-associated chronic pain. J Clin Pharmacol 2015. [Epub ahead of print]
37. Pagonabarraga J, Piñ ol G, Cardozo A, et al. Transdermal rotigotine improves sleep fragmentation in Parkinson's disease: results of the multicenter, prospective SLEEP-FRAM study. Parkinsons Dis 2015; 2015:131508.
38. Vallderiola F, Compta Y, Aparicio J, et al. Effects of night-time use of rotigotine on nocturnal symptoms in Parkinson's disease. Parkinsons Dis 2015; 2015:475630.